Want to see VOR full AI Analyst Report?
VOR Stock Chart & Stats
$24.01
$0.18(0.93%)
At close: 4:00 PM EDT
$24.01
$0.18(0.93%)
Day’s Range― - ―
52-Week Range$6.50 - $30.38
Previous Close$19.41
Volume948.25K
Average Volume (3M)1.16M
Market Cap
$1.13B
Enterprise Value$536.49M
Total Cash (Recent Filing)$466.13M
Total Debt (Recent Filing)$2.88M
Price to Earnings (P/E)―
Beta5.05
Next Earnings
Nov 11, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-325.79
Shares Outstanding59,162,292
10 Day Avg. Volume836,729
30 Day Avg. Volume1,163,314
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.90
Enterprise Value/Market Cap0.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-19.16K
Enterprise Value/Ebitda0.83
Forecast
1Y Price Target
$37.67Price Target Upside56.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-7.21
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Absolute DebtVery modest absolute debt reduces interest and refinancing pressure relative to a heavily leveraged company. This gives Vor greater flexibility to direct available capital toward clinical development and preserves some capacity to manage financing needs as programs advance.
Extended Cash RunwayA projected operating runway into early 2029 provides time to advance clinical programs without an immediate need for additional capital. That liquidity can support trial execution and milestone generation, although the runway still depends on continued cash management.
Phase 3 Enrollment MilestoneCompleting enrollment in a global registrational study is a meaningful development milestone that moves the program toward an efficacy and regulatory readout. It establishes a clearer path for assessing telitacicept’s potential and supports continued clinical value creation.
Bears Say
Pre-revenue BusinessZero revenue means Vor has not yet demonstrated commercial product demand or an operating revenue base. The company therefore remains dependent on clinical progress and external capital rather than internally generated sales to support its business and development plans.
Persistent Cash BurnConsistently negative operating and free cash flow indicates that the current business consumes substantial cash as it funds operations and development. Continued burn can reduce financial flexibility over time and may require further capital raising before programs generate revenue.
Deeply Negative EquityNegative stockholders’ equity signals a materially weakened capital structure despite low debt. It reduces balance-sheet flexibility, complicates the company’s financial profile, and leaves Vor more reliant on future operating improvement or financing activity to strengthen its position.
Vor Biopharma News
VOR FAQ
What was Vor Biopharma’s price range in the past 12 months?
Vor Biopharma lowest stock price was $6.50 and its highest was $30.38 in the past 12 months.
What is Vor Biopharma’s market cap?
Vor Biopharma’s market cap is $1.13B.
When is Vor Biopharma’s upcoming earnings report date?
Vor Biopharma’s upcoming earnings report date is Nov 11, 2026 which is in 21 days.
How were Vor Biopharma’s earnings last quarter?
Vor Biopharma released its earnings results on Aug 11, 2026. The company reported -$1.16 earnings per share for the quarter, missing the consensus estimate of -$0.704 by -$0.456.
Is Vor Biopharma overvalued?
According to Wall Street analysts Vor Biopharma’s price is currently Undervalued.
Does Vor Biopharma pay dividends?
Vor Biopharma does not currently pay dividends.
What is Vor Biopharma’s EPS estimate?
Vor Biopharma’s EPS estimate is -0.84.
How many shares outstanding does Vor Biopharma have?
Vor Biopharma has 59,162,292 shares outstanding.
What happened to Vor Biopharma’s price movement after its last earnings report?
Vor Biopharma reported an EPS of -$1.16 in its last earnings report, missing expectations of -$0.704. Following the earnings report the stock price went up 0.941%.
Which hedge fund is a major shareholder of Vor Biopharma?
Currently, no hedge funds are holding shares in VOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vor Biopharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.67 (56.88% Upside)
$37.67 (56.88% Upside)
Blogger Sentiment
Bullish
VOR Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.4%
Last 30 Days ▼ 8.4%
Last 30 Days ▼ 8.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-35.33%
12-Months-Change
Fundamentals
Return on Equity
-91.63%
Trailing 12-Months
Asset Growth
134.24%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Vor Biopharma
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
VOR Stock 12 Month Forecast
Average Price Target
$37.67
▲(56.88% Upside)
Technical Analysis
Codexis
―
Black Diamond Therapeutics
―
Atea Pharmaceuticals
―
Caribou Biosciences
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
11.17% Insiders
5.74% Mutual Funds
<0.01% Other Institutional Investors
72.57% Public Companies and
Individual Investors